The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study - 11/09/11
Support in part by Miles Pharmaceuticals, Inc.
Abstract |
OBJECTIVE: Our purpose was to examine the potential teratogenicity of calcium channel blockers. STUDY DESIGN: Six teratogen information services prospectively collected and followed up 78 women with first-trimester exposure to calcium channel blockers. Pregnancy outcome was compared (by paired t test or χ2 analysis) with that of a control group matched for maternal age and smoking. RESULTS: There was no increase in major malformations (2/66 = 3.0% [calcium channel blockers] vs 0% [nonteratogenic controls], p = 0.27); a fivefold increase was ruled out (baseline 2%, ⍺ = 0.05, β = 0.20). The defects reported were attributable to maternal diabetes or coingestion of teratogens. The increase in preterm delivery (28% [calcium channel blockers] vs 9% [nonteratogenic controls], p = 0.003), attributed to maternal disease by stepwise regression, was the most important factor responsible for the observed decrease in birth weight (mean -334 gm vs nonteratogenic controls, p = 0.08). CONCLUSION: This study suggests that calcium channel blockers do not represent a major teratogenic risk. (AM J OBSTET GYNECOL 1996;174:823-8.)
Le texte complet de cet article est disponible en PDF.Keywords : Calcium channel blockers, pregnancy, pregnancy complications, birth weight
Plan
 | From the Motherisk Program, Hospital for Sick Children,a the Pregnancy Healthline, Pennsylvania Hospital,b the Teratogen Information Service, University of South Florida,c the Nebraska Teratogen Project, University of Nebraska Medical Center,d the Indiana Teratogen Information Service, Indiana University Medical Center,e the Teratogen Information Service; University of London,f and the Pediatric and Medical Genetics Services.g |
| Reprint requests: L.A. Magee, MD, Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hospital for Sick Children, 555 University Ave., Toronto, Ontario, Canada M5G 1X8. |
 | 0002-9378/96 $5.00 + 0 6/1/68220 |
Vol 174 - N° 3
P. 823-828 - mars 1996 Retour au numéro
Article précédent
- Fetal RhD genotyping in fetal cells flow sorted from maternal blood
- Ossie Geifman-Holtzman, Ira M. Bernstein, Stanley M. Berry, Eliezer J. Holtzman, Theresa J. Vadnais, Mary Ann DeMaria, Diana W. Bianchi
- Is fetal neurologic and physical development accelerated in preeclampsia?
- Radha S. Chari, Steven A. Friedman, Eyal Schiff, Antoine Y. Frangieh, Baha M. Sibai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?